AI-generated summary
Thirty patients with myofascial pain syndrome were randomized to photobiomodulation with a 635 nm or 980 nm diode laser for five weeks. The authors report that both groups improved on pain and jaw function measures, with the 980 nm group showing greater pain reduction, and they attribute this to deeper tissue penetration. The authors note the small sample size and lack of a placebo control.
- Participants
- 30
- Who or what was studied
- Patients with myofascial pain syndrome (mandibular/masticatory muscle pain)
- Wavelengths
- 635, 980 nm
- Limits stated in the abstract
- The authors state the sample is small and there was no placebo control group.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Myofascial pain syndrome (MPS) is a common musculoskeletal disorder characterized by myofascial trigger points and muscle dysfunction. Photobiomodulation therapy (PBMT) with diode lasers has shown promise for analgesia and functional improvement in MPS management.
Aim
This study compared the efficacy of 635 nm and 980 nm diode lasers in alleviating pain and enhancing mandibular function in MPS patients.
Methods
Thirty patients were randomized into two groups Group A (635 nm, 0.5 W, 60 s, 38.2 J/cm²) and Group B (980 nm, 0.2 W, 60 s, 15.3 J/cm²), applied twice weekly for five weeks. Outcomes included visual analogue scale (VAS), Maximum Mouth Opening (MMO), lateral/protrusive movements (LM/PM), and surface electromyography (sEMG) at baseline, post-treatment, and one-month follow-up.
Results
Both groups showed significant improvements in all outcome measures (p < 0.001). VAS decreased from 7.6 ± 1.2 to 2.9 ± 1.3 (≈ 62% reduction) in the 635 nm group, and from 7.8 ± 1.1 to 2.1 ± 0.9 (≈ 73% reduction) in the 980 nm group (between-group p = 0.02). Maximum Mouth Opening (MMO) increased by 7.6 mm (34.5 ± 4.2 → 42.1 ± 3.2) in the 635 nm group versus 10.2 mm (34.0 ± 3.9 → 44.2 ± 2.9) in the 980 nm group (p = 0.01). Lateral movement (LM) improved by 2.3 mm vs. 2.8 mm, and Protrusive movement (PM) improved by 1.7 mm vs. 2.1 mm in the 635 nm and 980 nm groups, respectively. sEMG showed greater muscle activity reduction with 980 nm vs. 635 nm (Masseter: 47–51% vs. 39–40%; Temporalis: 43–44% vs. 36%; see(Table 3 for full data).
Conclusion
PBMT with 980 nm produced superior pain relief, muscle relaxation, and Mandibular function recovery compared to 635 nm, likely due to deeper tissue penetration. However, interpretation should consider the small sample size and lack of placebo control.
Trial Registration
ClinicalTrials.gov, NCT07069764. Registered retrospectively on 07 July 2025.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 980 nm, 635 nm
- Power
- 0.5 W, 0.2 W
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Randomized controlled trial, Visual analogue scale, Fluence, Trial registration, Sample size. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.